Holy Grail of COVID-19 Spike Protein Detoxification

Most people who received one of the COVID-19 shots ask me this question: “How do I get this out of my body.” The mRNA, adenoviral DNA products and the mRNA were developed without knowing how or when the genetic code would be broken down by the body. The synthetic mRNA on lipid nanoparticles is designed to resist human ribonucleases, so that it would last for a significant time and produce the protein product of your choice.

This would allow a normal human protein to be replaced in a rare condition like Fabry’s disease. It is problematic when the protein is the pathogenic SARS–CoV-2 spike. Although deoxyribonuclease is recommended for the breakdown of Janssen’s adenoviral genetic DNA (Janssen), this has not yet been extensively studied.

The vaccine injured can now seek treatment by dissolving spike protein. The respiratory infection activates spike protein by cellular proteases, including transmembrane serine protein 2, cathepsin and furin. These systems can be avoided with systemic vaccination and the production of spike protein in cells. The pathogenesis of vaccine-related injuries syndromes is thought to be caused by the accumulation of spike proteins in cells, tissues, organs, and cells.

Nattokinase, an enzyme, is made by fermenting soybeans and Bacillus subtilis. Natto has been used as an oral supplement. It is known to degrade fibrinogen, factor VII and factor VIII, and it has been shown to have cardiovascular benefits. My experience with all of the possible therapies and all the potential detoxification agents has shown me that nattokinase peptides and its related peptides offer the most promise to patients.

Tanikawa et al. The effect of nattokinase upon the spike protein in SARS-CoV-2 was studied by Tanikawa et al. They demonstrated in the first experiment that spike could be degraded in a dose-dependent and time-dependent manner in cell lysate preparations that could be used as vaccine recipients. The second experiment showed that the spike protein was degraded by nattokinase in infected SARS/CoV-2 cells. Oba and his colleagues carried out a similar experiment in 2021.

Nattokinase doses are in fibrinolytic units per gram. Purity can vary. Kurosawa and colleagues have shown in humans that after a single oral dose of 2000 FU D-dimer concentrations at six, and eight hours, and blood fibrin/fibrinogen degradation products at four hours after administration elevated significantly (p < 0.05, respectively).

An empiric starting dose would be 2000 FU twice daily. While pharmacokinetic and drug-drug interactions have not been completely studied, several years of over-the-counter use suggest that nattokinase may be safe. However, there are some caveats to consider: excessive bleeding; cautions about antiplatelet and anticoagulant drugs.

These findings suggest that nattokinase, and other similar products, such as serrapeptase, should be subject to well-funded preclinical and clinical research programs. The urgent need for treatment is what we face, in a similar fashion to the SARS-CoV-2 virus infection and empiric earlier therapy. To be able to evaluate the safety and efficacy for nattokinase as a treatment for vaccine injury or post-COVID syndromes, it will take 20 years.

Many people are suffering from illness right now. Emiric treatment seems to be justified due to the low risk of side effects and potential high reward. It is best to talk with your doctor, or consult a specialist who is skilled in holistic or naturopathic medicine and is familiar with the safety profile of Nattokinase in a variety of applications.

Reposted from Peter A. McCullough’s Substack

◇ References:

Tanikawa, T., Yu J. Yu J. Hsu k, Chen S. Ishii A. Yokogawa A. Suzuki R. Inoue Y. Kitamura m. Degradative effect of Nattokinase upon Spike Protein of SARS–CoV-2. Molecules. 2022 Aug 24;27(17):5405. doi: 10.3390/molecules27175405. PMID: 36080170; PMCID: PMC9458005.

Oba M. Rongduo W. Saito A. Okabayashi T. Yokota T. Yasuoka J. Sato Y. Nishifuji KM, Wake H. Nibu Y. Mizutani T. Natto, a Japanese fermented soy food, directly inhibits viral infection including SARS/CoV-2 in vitro. Biochem Biophys Res Commun. 2021 Sep 17;570:21-25. doi: 10.1016/j.bbrc.2021.07.034. Epub 2021 Jul 13. PMID: 34271432; PMCID: PMC8276596.

Kurosawa, Y., Nirengi S., Homma T., Esaki K. Ohta M. Clark JF. Hamaoka T. An oral nattokinase single-dose potentiates anti-coagulation profiles and thrombolysis. Sci Rep. 2015 Jun 25;5:11601. doi: 10.1038/srep11601. PMID: 26109079; PMCID: PMC4479826.

These EpochHealth articles are intended to be used as information and not as a substitute or replacement for individual medical advice. Refer to a trusted professional for your personal medical advice, diagnosis, treatment. Have a question? We are available at [email protected]